What is Automera?
Automera is a biotechnology company headquartered in Seattle, WA, dedicated to the advancement of autophagy-targeting chimera small molecules (AUTACs). AUTACs represent a novel therapeutic modality designed to harness the cell's natural degradation process, autophagy, to clear disease-causing proteins. The company's focus on this innovative approach positions it at the forefront of developing new treatments for a range of conditions where protein aggregation plays a significant role. This strategic investment will likely fuel further research and development, potentially accelerating the translation of its discoveries into clinical applications.
How much funding has Automera raised?
Automera has raised a total of $16M across 1 funding round:
Series A
$16M
Series A (2023): $16M with participation from Edbi and Xora Innovation
Key Investors in Automera
Edbi
EDBI is a global investor based in Singapore, focusing on high-growth technology sectors since 1991. The company aims to create value and empower businesses to build sustainable legacies through strategic investments.
Xora Innovation
Xora provides capital and support to deep tech entrepreneurs focused on transforming essential industries. The company's investments are primarily concentrated in three sectors: Compute Communications, Climate Energy, and AI in Physical Industries.
What's next for Automera?
With a recent Series A financing round, Automera is poised for significant growth and expansion. The company's strategic objective is to leverage this capital to further its research into AUTACs, potentially moving its lead candidates into later-stage development and clinical trials. The involvement of sophisticated investors like EDBI and Xora Innovation suggests a strong belief in Automera's scientific foundation and market potential. Future endeavors will likely involve expanding the research team, enhancing manufacturing capabilities, and forging strategic partnerships to bring its innovative therapies to patients. The company's trajectory indicates a move towards becoming a key player in the targeted protein degradation space.
See full Automera company page
